All You Need to Know About Karyopharm Therapeutics (KPTI) Rating Upgrade to BuyZacks Investment Research • 07/05/23
Karyopharm Initiates Pivotal Phase 3 Study of XPO1 Inhibitor Selinexor and Ruxolitinib in JAK Inhibitor (JAKi) Naïve MyelofibrosisPRNewsWire • 06/28/23
Antengene Announces XPOVIO® plus Bortezomib and Dexamethasone Included for Reimbursement by the PBS in Australia for the Treatment of Relapsed and/or Refractory Multiple MyelomaPRNewsWire • 06/01/23
Karyopharm to Present New Selinexor Data at the 2023 American Society of Clinical Oncology and European Hematology Association Annual MeetingsPRNewsWire • 05/23/23
Karyopharm Therapeutics (KPTI) Reports Q1 Loss, Tops Revenue EstimatesZacks Investment Research • 05/04/23
Karyopharm Reports First Quarter 2023 Financial Results and Highlights Recent Company ProgressPRNewsWire • 05/04/23
Karyopharm Announces Presentation of Interim Data from Phase 2 Study of Single-Agent Eltanexor in Relapsed/Refractory (R/R) Higher-Risk Myelodysplastic Neoplasms (MDS) at 17th International Congress on MDSPRNewsWire • 05/03/23
Will Karyopharm Therapeutics (KPTI) Report Negative Q1 Earnings? What You Should KnowZacks Investment Research • 04/27/23
Karyopharm Announces Presentation of Updated Phase 1 Selinexor Data in Patients with Treatment-Naïve Myelofibrosis at AACR 2023PRNewsWire • 04/18/23
Karyopharm To Present Data from Phase 1 Study of Selinexor in Patients with Treatment-Naïve Myelofibrosis at AACR and to Host Investor Webcast on April 18thPRNewsWire • 04/14/23
Karyopharm Therapeutics: Expanding Beyond The Crowded Multiple Myeloma MarketSeeking Alpha • 03/20/23
Karyopharm Announces Updated Selinexor Data in Patients with Treatment-Naïve Myelofibrosis to be Presented at AACR 2023PRNewsWire • 03/14/23
Karyopharm and Menarini Group Receive Full Marketing Authorization from the UK Medicines & Healthcare Products Regulatory Agency for NEXPOVIO® (selinexor) in Combination with Bortezomib and Dexamethasone for the Treatment of Adult Patients with Multiple MPRNewsWire • 02/21/23
Karyopharm Therapeutics (KPTI) Reports Q4 Loss, Misses Revenue EstimatesZacks Investment Research • 02/15/23
Karyopharm Reports Fourth Quarter and Full Year 2022 Financial Results and Highlights Recent Company ProgressPRNewsWire • 02/15/23
Karyopharm to Report Fourth Quarter and Full Year 2022 Financial Results on February 15, 2023PRNewsWire • 02/08/23
Analysts Estimate Karyopharm Therapeutics (KPTI) to Report a Decline in Earnings: What to Look Out forZacks Investment Research • 02/07/23